Educating Medical Professionals for that “Rare Encounter”
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
2023 brings increased expectations from the FDA for patient-focused drug development (PFDD). Medical Affairs organizations need to develop new skills to put the patient voice at the center of drug, device, and diagnostic development and evaluation.
This webinar will discuss how MA colleagues are best positioned to explore the fusion of PE and PED in the post-launch phase, including generation and use of RWD and RW evidence, and will share guidance and information on several industry-supported resources, to enable MA colleagues to implement PE and evidence strategies in their function.
In this episode, experts discuss patient-centricity strategies and actions that make patient-first thinking the heart of your organization’s plans.
MAPS speaks with Eric Peacock, co-Founder and CEO of MyHealthTeam, about the alignment between social justice and business best-practices to promote health equity using patient communities.
MyHealthTeam presents three case studies and four actionable steps to help improve your Medical Affairs Programs for patients.
Last month, Medical Affairs and clinical experts from six organizations came together to help make clinical trials more accessible to and better understood by people facing vitiligo. You can do this in your therapeutic area.
MAPS speaks with MyHealthTeams Cofounder and CEO, Eric Peacock, about how health communities can help the biopharmaceutical industry develop new products that truly make a difference in patients’ lives.
This MAPS podcast introduces listeners to social listening to gather insights and discusses implementation, value and technologies.
The webinar will provide a snapshot of insights on what matters to patients and how pharma fares in terms of patient centricity based on a new patient centricity benchmarking survey piloted in 2019.
